<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860870</url>
  </required_header>
  <id_info>
    <org_study_id>CLEN</org_study_id>
    <nct_id>NCT03860870</nct_id>
  </id_info>
  <brief_title>Response to Clenbuterol in Humans</brief_title>
  <official_title>Detectability of Clenbuterol and Physiological Response in Human Skeletal Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the long half-life (~36 hr) of clenbuterol, detection methods such as dried blood
      spots (DBS) are a potentially suitable method to easily and non-invasively detect doping
      misuse of this compound for several days after ingestion. If, and how long, the compound can
      be detected by DBS has not yet been investigated but is of interest due to its potential in
      doping-control. The aim is to evaluate whether abuse of clenbuterol can be detected at
      relevant concentration levels in samples obtained using DBS and to assess the physiological
      response to clenbuterol in skeletal muscle..
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood clenbuterol concentration</measure>
    <time_frame>Before (baseline) as well as 3, 8, 24, 72, 168 and 240 hours after administration of clenbuterol</time_frame>
    <description>Concentration of clenbuterol in dried blood spots</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood clenbuterol concentration</measure>
    <time_frame>Before (baseline) as well as 3, 8, 24, 72, 168 and 240 hours after administration of clenbuterol</time_frame>
    <description>Concentration of clenbuterol in venous blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine clenbuterol concentration</measure>
    <time_frame>Before (baseline) as well as 3, 8, 24, 72, 168 and 240 hours after administration of clenbuterol</time_frame>
    <description>Concentration of clenbuterol in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>Before (baseline) and 2.5 hours after administration of clenbuterol</time_frame>
    <description>Maximal voluntary isometric contraction in N/m2 of the quadriceps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle signalling</measure>
    <time_frame>Before (baseline) and 2.5 hours after administration of clenbuterol</time_frame>
    <description>Protein kinase A phosphorylation in vastus lateralis biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma K+</measure>
    <time_frame>Before (baseline) as well as 2 and 5 hours after administration of clenbuterol</time_frame>
    <description>Venous plasma K+ concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mTOR signalling</measure>
    <time_frame>Before (baseline) as well as 2.5 hours after administration of clenbuterol</time_frame>
    <description>mTOR phosphorylation in vastus lateralis biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic rate</measure>
    <time_frame>Before (baseline) as well as 2 and 5 hours after administration of clenbuterol</time_frame>
    <description>Respriatory exchange ratio of oxygen and CO2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Clenbuterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects ingest 80 micrograms of clenbuterol tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clenbuterol Oral Product</intervention_name>
    <description>Subjects ingest 4x20 microgram clenbuterol tablets</description>
    <arm_group_label>Clenbuterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Male

          -  18-40 years of age

          -  No known contraindications for anabolic drugs (e.g. cancer)

        Exclusion Criteria:

          -  Abnormal ECG

          -  Steroid abuse

          -  Ongoing use of prescription medication

          -  heavy resistance training more than 2 times weekly

          -  Disease deemed by the MD to infer a risk to participate in the trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>August Krogh Building</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Hostrup, PhD</last_name>
      <phone>+4524474785</phone>
      <email>mhostrup@nexs.ku.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dried blood spots</keyword>
  <keyword>skeletal muscle biopsies</keyword>
  <keyword>muscle strength</keyword>
  <keyword>muscle signaling</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clenbuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

